领先制药公司GSK plc (LSE/NYSE:GSK)今日宣布，欧洲药品管理局 (EMA)已开始审查其佐剂重组呼吸道合胞病毒 (RSV)疫苗Arexvy用于18岁及以上成人的申请。该疫苗目前已获准用于老年人群，预计将在2026年上半年获得监管决定。

今年4月，美国FDA关键顾问小组投票决定将RSV疫苗的使用范围扩大至50至59岁高风险成年群体，为保险公司为该年龄段人群报销疫苗铺平道路，该投票决定也被视为FDA同意60岁以下高风险群体接受接种RSV疫苗的重要信号。

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

在现代医学不断追求突破的征程中，呼吸道合胞病毒（RSV）的预防和治疗一直是备受瞩目的难题。近期，若顺利，默沙东的Clesrovimab有望获得FDA批准，成为全球第三款RSV预防单抗。有望近期获批Clesrovimab（MK-1654）是默沙东开发的 ...

此次人事变动并非孤立事件。2025年4月初，赛诺菲任命GSK前研发负责人Chris ...

Investing.com -- GSK (NYSE: GSK )周五表示，欧洲药品管理局 (EMA)已接受其申请，将呼吸道合胞病毒 (RSV)疫苗Arexvy的使用范围扩大至18岁及以上成人。

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

OPEN The FTSE 100 was expected to open 38.4 points lower ahead of the bell on Friday after closing 0.23% higher in the ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...